JGC
TARA icon

J. Goldman & Co’s Protara Therapeutics TARA Stock Holding History

J. Goldman & Co’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.46M Buy
+856,247
New +$5.07M 0.13% 200
2025
Q4 		– Sell
-100,350
Closed -$437K – 736
2025
Q3 		$437K Sell
100,350
-27,000
-21% -$87.4K 0.01% 388
2025
Q2 		$386K Sell
127,350
-18,991
-13% -$65.5K 0.01% 396
2025
Q1 		$623K Buy
146,341
+4,593
+3% +$20.5K 0.02% 393
2024
Q4 		$748K Buy
+141,748
New +$458K 0.02% 349

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

J. Goldman & Co's TARA Position: Q1 2026 in Review

J. Goldman & Co opened a new position in Protara Therapeutics (TARA) in Q1 2026: 856,247 shares worth $4.46M. The stake represents 0.13% of the portfolio and ranks #200 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in TARA as recently as Q3 2025.

J. Goldman & Co first reported a position in TARA in Q4 2024 and has held it in 5 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • J. Goldman & Co held 856,247 shares of Protara Therapeutics worth $4.46M as of Q1 2026.
  • Protara Therapeutics was a new J. Goldman & Co position in Q1 2026.
  • Protara Therapeutics made up 0.13% of J. Goldman & Co's portfolio in Q1 2026, its #200 holding.
  • J. Goldman & Co first reported a position in Protara Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.